tbuckley/cabot-search huggingface dataset:
Characteristics of conversion to 2nd line treatment in sorafenib-treated advanced hepatocellular carcinoma patients
Authors: S. Ogasawara, T. Chiba, Y. Ooka, E. Suzuki, M. Yokoyama, T. Wakamatsu, M. Inoue, T. Saito, A. Tawada, O. Yokosuka
Journal: Journal of Hepatology (2017)
Ras mutations in patients with myelodysplastic syndrome: Incidence and prognostic value
Authors: M. Constantinidou, G. Chalevelakis, T. Economopoulos, M. Koffa, T. Liloglou, C. Anastasiou, A. Yalouris, D. A. Spandidos, S. Raptis
Journal: Blood (1995)
Hepatotropic effects of granulocyte colony stimulating factor in non-alcoholic fatty liver disease: beyond marrow cell mobilization
Authors: S.B. Ahn, D.W. Jun, H.W. Oh, W.K. Saeed, Y.J. Chae, J.S. Lee, Y.J. Chae, J.Y. Jeong, H.W. Oh, H.T. Kang, J.H. Sohn, E.C. Jang, B.-K. Kang
Journal: Journal of Hepatology (2017)
Venous thromboembolism in patients with glioblastoma: Risk factors and prognostic importance.
Authors: Natasha Catherine Edwin, Paul Elson, Manmeet Singh Ahluwalia, Alok A. Khorana
Journal: Journal of Clinical Oncology (2015)

e13027 Background: Venous thromboembolism (VTE) is a common complication of glioblastoma (GBM). Impact of VTE on mortality and risk factors for VTE in GBM are incompletely understood. Methods: We conducted a retrospective cohort study of consecutive GBM patients at Cleveland Clinic (2008-13). Demographic characteristics, comorbid illnesses, performance status (KPS), baseline blood counts and chemistry, tumor size and treatment administered were recorded. Information on objectively proven VTE was captured. Proportional hazards models were used to analyze associations between risk factors and VTE, and VTE and overall survival (OS) measured from GBM diagnosis. Results: The study population comprised 361 patients. Median age was 63 (range, 19-96) years. Of these, 141 (39%) developed VTE, including 105 deep vein thromboses and 15 pulmonary emboli. Median time to VTE was 2 months (range, 0-11.4 years). Bevacizumab was associated with higher risk of VTE in univariate analysis. However, in multivariate analysis, only elevated body mass index (HR 1.3, 95% CI 1.1-1.5), older age (HR 1.4, 1.1-1.7), paresis (HR 1.7,1.1-2.5), extent of resection (HR 1.6, 1.1-2.4), and hemoglobin (HR 1.5,1-2.1) were significant independent predictors of VTE. Median survival was 14.1 months, but worsened in patients with VTE (6.1 vs 15 months for without VTE). In multivariate analysis, VTE continued to be associated with worsened survival (HR 1.52, 95% CI 1.19-1.95) as were older age, poor KPS, extent of resection and lack of adjuvant therapy. Conclusions: VTE is highly prevalent and associated with worsened survival in patients with GBM. We have identified risk factors for VTE that may be used to develop a risk assessment model in this population.
UTILIDAD DEL DRENAJE COLECISTODUODENAL TRANSPAPILAR COMO MÉTODO DE PREVENCIÓN DE COMPLICACIONES Y NECESIDAD DE REINGRESO EN PACIENTES MAYORES Y/O DE ALTO RIESGO QUIRÚRGICO QUE PRESENTAN COLELITIASIS ASOCIADA A COLEDOCOLITIASIS
Authors: B Moreira, A Germade, L Pérez, R Castillo, K De Jesús, S Maestro, F Santos, F Igea, J Barcenilla, A Pérez, E Saracibar, R Madrigal, A Santamaria
Journal: Endoscopy (2015)

Introducción: La cirugía de las enfermedades de la vía biliar ha cambiado con el progreso de las técnicas endoscópicas. Al día de hoy, el tratamiento de elección de la colelitiasis sintomática y colecistitis aguda es quirúrgico, mientras que el tratamiento de la coledocolitiasis es la CPRE. Sin embargo, en pacientes mayores, con alto riesgo quirúrgico, la colecistectomía, implica alta morbimortalidad, por lo que otras alternativas deben ser estudiadas.
Affinity‐Immobilization of VEGF on Laminin Porous Sponge Enhances Angiogenesis in the Ischemic Brain
Authors: Mio Oshikawa, Kei Okada, Naoko Kaneko, Kazunobu Sawamoto, Itsuki Ajioka
Journal: Advanced Healthcare Materials (2017)

Ischemic brain stroke is caused by blood flow interruption, leading to focal ischemia, neuron death, and motor, sensory, and/or cognitive dysfunctions. Angiogenesis, neovascularization from existing blood vessel, is essential for tissue growth and repair. Proangiogenic therapy for stroke is promising for preventing excess neuron death and improving functional recovery. Vascular endothelial growth factor (VEGF) is a critical factor for angiogenesis by promoting the proliferation, the survival, and the migration of endothelial cells. Here, angiogenic biomaterials to support injured brain regeneration are developed. Porous laminin (LN)‐rich sponge (LN‐sponge), on which histidine‐tagged VEGF (VEGF‐Histag) is immobilized via affinity interaction is developed. In an in vivo mouse stroke model, transplanting VEGF‐Histag‐LN‐sponge produces remarkably stronger angiogenic activity than transplanting LN‐sponge with soluble VEGF. The findings indicate that using affinity interactions to immobilize VEGF is a practical approach for developing angiogenic biomaterials for regenerating the injured brain.
Spatiotemporal functional genomics uncovers cell circuits triggering liver disease biology of hepatitis C virus infection
Authors: J. Lupberger, T. Croonenborghs, M. Jovanovic, P. Mertins, N. Van Renne, S. Bandiera, H.E. Sagire, C. Thumann, J. Kozubek, K. Kiani, N. Bardeesy, Y. Hoshida, S. Carr, A. Regev, M.B. Zeisel, N. Pochet, T.F. Baumert
Journal: Journal of Hepatology (2017)
RET Signaling in Prostate Cancer
Authors: Kechen Ban, Shu Feng, Longjiang Shao, Michael Ittmann
Journal: Clinical Cancer Research (2017)

Purpose: Large diameter perineural prostate cancer is associated with poor outcomes. GDNF, with its coreceptor GFRα1, binds RET and activates downstream pro-oncogenic signaling. Because both GDNF and GFRα1 are secreted by nerves, we examined the role of RET signaling in prostate cancer.Experimental Design: Expression of RET, GDNF, and/or GFRα1 was assessed. The impact of RET signaling on proliferation, invasion and soft agar colony formation, perineural invasion, and growth in vivo was determined. Cellular signaling downstream of RET was examined by Western blotting.Results: RET is expressed in all prostate cancer cell lines. GFRα1 is only expressed in 22Rv1 cells, which is the only line that responds to exogenous GDNF. In contrast, all cell lines respond to GDNF plus GFRα1. Conditioned medium from dorsal root ganglia contains secreted GFRα1 and promotes transformation-related phenotypes, which can be blocked by anti-GFRα1 antibody. Perineural invasion in the dorsal root ganglion assay is inhibited by anti-GFRα antibody and RET knockdown. In vivo, knockdown of RET inhibits tumor growth. RET signaling activates ERK or AKT signaling depending on context, but phosphorylation of p70S6 kinase is markedly increased in all cases. Knockdown of p70S6 kinase markedly decreases RET induced transformed phenotypes. Finally, RET is expressed in 18% of adenocarcinomas and all three small-cell carcinomas examined.Conclusions: RET promotes transformation associated phenotypes, including perineural invasion in prostate cancer via activation of p70S6 kinase. GFRα1, which is secreted by nerves, is a limiting factor for RET signaling, creating a perineural niche where RET signaling can occur. Clin Cancer Res; 23(16); 4885-96. ©2017 AACR.
Association Between Long-term Quinine Exposure and All-Cause Mortality
Authors: Laurence Fardet, Irwin Nazareth, Irene Petersen
Journal: JAMA (2017)

Quinine has been used since the 1930s to treat idiopathic muscular cramps. However, in 2006, because of efficacy and safety issues, the US Food and Drug Administration cautioned about this off-label use of quinine, citing “665 reports of adverse events with serious outcomes…including 93 deaths.”1 Despite warnings, quinine is still prescribed to individuals with idiopathic muscular cramps. Furthermore, many drinks such as bitter lemon or tonic waters contain quinine, and hence, many may be exposed to quinine daily. This study explored the association between long-term quinine exposure and all-cause mortality.
Portal vein infiltration in patients with hepatocellular carcinoma: the impact of correct classification
Authors: R. Kloeckner, V. Steinle, S. Koch, D.P. Dos Santos, J. Marquardt, M. Sprinzl, H. Lang, C. Dueber, P. Galle, M. Woerns, A. Weinmann
Journal: Journal of Hepatology (2017)
Erratum: Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice (American Journal of Respiratory and Critical Care Medicine (1993) 148 (1541-1546))
Authors: B Ji, C Truffot-Pernot, C Lacroix, M C Raviglione, R J O'Brien, P Olliaro, G Roscigno, J Grosset
Journal: American Journal of Respiratory and Critical Care Medicine (1994)
Unraveling a Novel Mechanism of RUNX1 Activity in Familial Platelet Disorder with Associated Myeloid Malignancy
Authors: Halah I. Alkadi, Tatiana S. Karpova, Erika Mijin Kwon, Lisa J. Garrett, Yongxing Gao, Stephen Wincovitch, Anfal Alsadhan, James J. Greene, David A. Ball, Linzhao Cheng, April D. Sorrell, Paul P. Liu
Journal: Blood (2016)
Molecular Characterization of Long Non-Coding RNA CASC15 in Leukemogenesis
Authors: Jorge R. Contreras, Thilini Fernando, Tiffany M Tran, Matteo Zampini, Norma Iris Rodriguez-Malave, Jayanth Kumar Palanichamy, Jasmine Gajeton, Nolan Ung, David Casero, Giuseppe Basso, Martina Pigazzi, Dinesh S. Rao
Journal: Blood (2016)
Comparison of four Fitbit and Jawbone activity monitors with a research-grade ActiGraph accelerometer for estimating physical activity and energy expenditure
Authors: Mary T Imboden, Michael B Nelson, Leonard A Kaminsky, Alexander HK Montoye
Journal: British Journal of Sports Medicine (2017)

Background/aim Consumer-based physical activity (PA) monitors have become popular tools to track PA behaviours. Currently, little is known about the validity of the measurements provided by consumer monitors. We aimed to compare measures of steps, energy expenditure (EE) and active minutes of four consumer monitors with one research-grade accelerometer within a semistructured protocol. Methods Thirty men and women (18–80 years old) wore Fitbit One (worn at the waist), Fitbit Zip (waist), Fitbit Flex (wrist), Jawbone UP24 (wrist) and one waist-worn research-grade accelerometer (ActiGraph) while participating in an 80 min protocol. A validated EE prediction equation and active minute cut-points were applied to ActiGraph data. Criterion measures were assessed using direct observation (step count) and portable metabolic analyser (EE, active minutes). A repeated measures analysis of variance (ANOVA) was used to compare differences between consumer monitors, ActiGraph, and criterion measures. Similarly, a repeated measures ANOVA was applied to a subgroup of subjects who didn’t cycle. Results Participants took 3321±571 steps, had 28±6 active min and expended 294±56 kcal based on criterion measures. Comparatively, all monitors underestimated steps and EE by 13%–32% (p&lt;0.01); additionally the Fitbit Flex, UP24, and ActiGraph underestimated active minutes by 35%–65% (p&lt;0.05). Underestimations of PA and EE variables were found to be similar in the subgroup analysis. Conclusion Consumer monitors had similar accuracy for PA assessment as the ActiGraph, which suggests that consumer monitors may serve to track personal PA behaviours and EE. However, due to discrepancies among monitors, individuals should be cautious when comparing relative and absolute differences in PA values obtained using different monitors.
Adipocyte fatty acid binding protein in cirrhosis: increased hepatic gene expression and plasma levels and correlation with clinical outcomes
Authors: I. Graupera, M. Coll, E. Pose, C. Elia, S. Piano, E. Solà, D. Blaya, P. Huelin, C. Solé, R. Moreira, G. de Prada, N. Fabrelles, M. Morales, P. Sancho-Bru, P. Ginès
Journal: Journal of Hepatology (2017)
PD-1+ CD8+ T cells as immunological biomarkers for the safe discontinuation of anti-viral therapy in chronic hepatitis B
Authors: N. Le Bert, L. Rivino, U.S. Gill, Y. Cheng, K. Kunasegaran, D.Z. Tan, E. Becht, N.K. Hansi, G.R. Foster, E.W. Newell, P.T.F. Kennedy, A. Bertoletti
Journal: Journal of Hepatology (2017)
Abstract 258: Nanoparticle-mediated Targeting of a Chemical Inhibitor of Drp1 to the Mitochondria Induces Cardioprotection From Myocardial Ischemia-reperfusion Injury
Authors: Ayako Ishikita, Tetusya Matoba, Gentaro Ikeda, Kensuke Egashira
Journal: Circulation Research (2015)

Background: Mitochondria (MITO) injury including MITO permeability transition pore (mPTP) opening plays a major role in the mechanism of ischemia-reperfusion (IR) injury. Intravenous administration of an inhibitor of mPTP opening, cyclosporine A, can reduce IR injury in animals and patients with acute myocardial infarction (MI), however; the power of cardioprotection by cyclosporine A is insufficient. We tested the hypothesis that nanoparticle-mediated targeting of Mdivi1, a chemical inhibitor of Drp1, to MITO enhances cardioprotection from IR injury. Methods and Results: We formulated poly(lactic acid/glycolic acid) (PLGA) nanoparticles containing Mdivi1 (Mdivi1-NP) or FITC (FITC-NP). In neonatal rat cardiomyocytes, PLGA nanoparticles accumulated in MITO after the addition of hydrogen peroxide (H2O2) that represents oxidative stress during IR (Fig.A). Treatment with Mdivi1-NP reduced H2O2-induced MITO division and cardiomyocyte death (Fig.B). This Mdivi1-NP cardioprotective effect was not seen over adenovirus harboring Drp1 shRNA transduced cardiomyocyte. In an in vivo and ex vivo murine model, treatment with Mdivi1-NP at the time of reperfusion reduced infarct size more effectively than Mdivi1 alone (Fig.C). Interestingly, Mdivi1-NP inhibited the leakage of cytochrome c to cytosol and MITO swelling, and reduced IR injury in both wildtype and cyclophilin D (a key regulatory molecule for mPTP opening)-KO mice (Fig.D). Conclusions: Mdivi1-NP enhanced cardioprotection against IR injury through mechanisms independent of mPTP opening. Mdivi1-NP can be a novel cardioprotective strategy in acute MI.
MEN2 Syndrome-Related Medullary Thyroid Carcinoma with Focal Tyrosine Hydroxylase Expression: Does It Represent a Hybrid Cellular Phenotype or Functional State of Tumor Cells?
Authors: Ozgur Mete, Ahmed Essa, Anil Bramdev, Navendren Govender, Runjan Chetty
Journal: Endocrine Pathology (2017)
The NLRP3 inflammasome is activated in liver tissue of patients with newly diagnosed chronic hepatitis B virus infection
Authors: G. Germanidis, A. Molyvdas, G. Loli, P. Hytiroglou, T. Vassiliadis, N. Lazaridis, P. Morfesis, P. Zebekakis, A.E. Germenis, M. Speletas
Journal: Journal of Hepatology (2017)
Prospective validation of a score to predict hepatocellular carcinoma in patients with hepatitis C cirrhosis that takes into account sustained virological response. Influence of direct-acting antivirals
Authors: A. Castaño, C. Alvarez-Navascues, C. Rodriguez-Escaja, M.A. de Jorge, E. Rubio, L. Gonzalez-Dieguez, M. Varela, V. Cadahia, R. Manuel
Journal: Journal of Hepatology (2017)
Persistence of Human Parvovirus B19 in Multipotent Mesenchymal Stromal Cells Expressing the Erythrocyte P antigen: Implications for Transplantation
Authors: Mikael Sundin, Anna Lindblom, Claes Örvell, A. John Barrett, Berit Sundberg, Emma Watz, Agneta Wikman, Kristina Broliden, Katarina Le Blanc
Journal: Blood (2008)
Circulating tumor DNA (ctDNA) as predictive biomarker in NSCLC patients treated with nivolumab
Authors: F. Passiglia, A. Perez, A. Listì, M. Castiglia, E. Musso, C. Ancona, S. Rizzo, M. Alù, L. Blasi, A. Russo
Journal: Annals of Oncology (2017)
Impact of modest weight reduction on liver histology, portal pressure, and clinical events in patients with compensated cirrhosis due to nonalcoholic steatohepatitis
Authors: J. Bosch, S. Harrison, V. Ratziu, M. Shiffman, A. Diehl, S. Caldwell, D. Rockey, R. Ghalib, P. Thuluvath, M. Abdelmalek, R. Aguilar, C. Jia, B. Mccolgan, R. Myers, M. Subramanian, J. McHutchison, Z. Goodman, N. Afdhal, A. Sanyal
Journal: Journal of Hepatology (2017)
A territory-wide study on the seroprevalence of hepatitis B and C virus in the general population in Hong Kong, China
Authors: S.H.K. Liu, W.-K. Seto, D.K.-H. Wong, J.C.-H. Yuen, Y.F.F. Lam, K. Shing, M. Cheung, W.P.E. To, K.L.M. Ko, L.Y.L. Mak, C.-L. Lai, M.-F. Yuen
Journal: Journal of Hepatology (2017)
Uromodulinopathies May Show a Wider Phenotypic Spectrum and Be Responsible of as Many as 3% of Unspecific ESRF Cases
Authors: Amoroso Antonio, Benoni Simona, Giachino Daniela, Mandrile Giorgia, Tavecchia Marta, Bruno Massimo, Basolo Bruno, Campo Andrea, Bossi Paolo, Priasca Giancarlo, Giraudi Roberta, Savoldi Silvana, Stratta Piero, Marchi Mario De
Journal: Journal of the American Society of Nephrology (2008)
The Controversial Epidemiology of Left Ventricular Dysfunction in Patients With Myotonic Dystrophy Type 1
Authors: Vincenzo Russo, Andrea Antonio Papa, Gerardo Nigro
Journal: JAMA Cardiology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results.
Authors: Vicky Makker, Fernando O. Recio, Ling Ma, Ursula Matulonis, Jennifer O'Hara Lauchle, Hema Parmar, Houston Gilbert, Yulei Wang, Hartmut Koeppen, Jill M Spoerke, Mark Lackner, Carol Aghajanian
Journal: Journal of Clinical Oncology (2014)

5513 Background: Treatment options for patients with recurrent or persistent endometrial cancer (EC) are limited. The PI3K/AKT/mTOR pathway has been implicated in the pathogenesis of EC. This single arm, open-label trial was designed to evaluate the activity of GDC-0980, a dual PI3K/mTOR inhibitor, in patients with advanced EC. NCT01455493. Methods: Patients with recurrent or persistent EC treated with 1 or 2 prior lines of chemotherapy but no prior PI3K/mTOR inhibitor received oral GDC-0980 40 mg daily on a 28-day cycle until progression or intolerable toxicity. Type I/II diabetics requiring insulin were excluded. The primary endpoints were progression-free survival (PFS) at 6 months and objective response rate (ORR). Archival tissue samples were collected for PI3K pathway biomarker analysis. Results: A total of 56 women were enrolled including 13 (23%) with well-controlled diabetes at study entry. Discontinuation reasons were disease progression, 24 (43%); adverse events, 13 (23%); withdrawal by subject, 12 (21%). Frequency of Grade 3/4 related adverse events in all patients were hyperglycemia (46%), rash (30%), colitis (5%), and pneumonitis (4%). At 6 months, 20% of patients were progression free (K-M estimate 95% CI: 7%-33%). ORR was 9% (unconfirmed). Median PFS was 3.5 months (95% CI: 2.7-3.7 months). Median time on study was 69 (12-226) days for non-diabetic and 27(4-84) days for diabetic patients. Discontinuation prior to first tumor assessment occurred in 19 patients, with 8/13 diabetics discontinued prior to Cycle 2, due to hyperglycemia. Dose reductions were required for 4 (31%) diabetics and 18 (42%) non-diabetics. Evaluable archival tumor samples were obtained from 44 (85%) patients, and 52% of patients had at least one alteration in PIK3CA, PTEN or AKT1. All 3 patients with a confirmed response had at least one alteration in a PI3K pathway gene. Conclusions: Evaluation of the anti-tumor activity of 40mg GDC-0980 daily was limited by tolerability, especially in diabetic patients. The trial provides data about the PI3K pathway mutation frequency in patients with recurrent EC and suggests that patients with a PI3K pathway mutation may have derived enhanced benefit from GDC-0980. Clinical trial information: NCT01455493.
Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era
Authors: Anna Alperovich, Connie Batlevi, Katy Smith, Zhitao Ying, Jacob D Soumerai, Amanda R Copeland, Erel Joffe, Philip Caron, Pamela Drullinsky, John F Gerecitano, Audrey Hamilton, Paul A Hamlin, Steven M Horwitz, Andrew M Intlekofer, Anita Kumar, Matthew J Matasar, Alison J. Moskowitz, Craig H Moskowitz, Ariela Noy, Maria Lia Palomba, Carol S Portlock, Craig S Sauter, David J Straus, Andrew D. Zelenetz, Ai Ni, Venkatraman E Seshan, Anas Younes
Journal: Blood (2016)
Hepatic and non-hepatic events after obtaining a SVR in patients with genotype 1b liver cirrhosis-short time follow-up-single center experience
Authors: A. Trifan, A.M. Singeap, S. Chiriac, T. Cuciureanu, C.C. Prelipcean, I. Ciortescu, C. Cojocariu, C. Sfarti, C. Mihai, G. Stefanescu, L. Gheorghe, S. Iacob, C. Stanciu
Journal: Journal of Hepatology (2017)
New direct action antivirals containing regimes to treat patients with hepatitis C chronic infection: first results from a national real-world registry of the Brazilian Hepatology Society
Authors: H. Cheinquer H, H.S. Coelho, R.S. Aires, E.D. Quintela, C. Lobato, J.E.M. Filho, L.B. Lima, L.A. Borba, M.G. Pessoa, G.F. Silva, E.B. Hyppolito, C.P. Ivantes, R.F. Rezende, C.B. Mello, E.A. Lopes, H. Sette, J. Lima, A.P. Ferreira, F.D. Souto, F.V. Nascimento, G.M. Gomide, I. Altikes, P.A. Pinto, M.A. Pedroso, G.S. Pereira, A.C. Martinelli, L.F. Gonçalves, R.L. Garcia, L.C. Mendes, F.P. Pessoa, M.G. Ferraz, D.B. Terrabuio, N.A. Figueira, P.A. Ferreira, R.P.F. Filho, R.A. Silva, C.M. Rocha, A.C. Lyra, C.V. Tovo, E. Strauss, A.S. Evangelista, E.R. Parise
Journal: Journal of Hepatology (2017)